HOMA-PULSE Observational Study, AF Ablation, 120+ Patients
Summary
HOMA-PULSE is a prospective observational study (NCT07551947) investigating whether insulin resistance, measured by the HOMA-IR index, predicts pulsed field ablation outcomes in atrial fibrillation patients. The study will enroll at least 120 non-diabetic patients undergoing their first AF ablation using pulsed field ablation technology at Cardiocentrum, AGEL Hospital Trinec-Podlesi, Czech Republic. Researchers will measure fasting glucose and insulin levels along with additional biomarkers including GDF-15, hs-CRP, NT-proBNP, IL-6, and IL-1beta.
“HOMA-PULSE is a prospective observational study enrolling at least 120 non-diabetic patients undergoing their first AF ablation using pulsed field ablation at the Cardiocentrum, AGEL Hospital Trinec-Podlesi, Czech Republic.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
HOMA-PULSE is a newly registered prospective observational clinical trial (NCT07551947) investigating whether insulin resistance, as measured by the HOMA-IR index, can predict the success of pulsed field ablation in treating atrial fibrillation. The study plans to enroll at least 120 non-diabetic patients undergoing their first AF ablation using pulsed field ablation technology at a single site in the Czech Republic. Blood biomarkers including HOMA-IR, GDF-15, hs-CRP, NT-proBNP, IL-6, and IL-1beta will be measured pre-procedure.
Healthcare providers and clinical investigators involved in cardiac ablation research should note this study addresses a gap in the literature—currently no prospective study has systematically examined whether insulin resistance predicts ablation outcomes with the newest pulsed field ablation technology. The study's findings could influence patient selection and treatment planning for AF ablation procedures.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Insulin Resistance as a Predictor of Pulsed Field Ablation Success in Atrial Fibrillation (HOMA-PULSE)
Observational NCT07551947 Kind: OBSERVATIONAL Apr 27, 2026
Abstract
This study investigates whether insulin resistance, a metabolic condition where the body's cells respond poorly to insulin, can predict the success of atrial fibrillation (AF) ablation using pulsed field ablation (PFA) technology.
Atrial fibrillation is the most common heart rhythm disorder, affecting 2-4% of adults. Catheter ablation is an effective treatment, but 20-40% of patients require a repeat procedure. Identifying patients at higher risk of ablation failure could improve treatment planning and outcomes.
Scientific evidence suggests that insulin resistance - which can exist for years before diabetes develops - may contribute to electrical and structural changes in the heart that promote AF. However, no prospective study has systematically examined whether insulin resistance measured by the HOMA-IR index predicts ablation outcomes, particularly with the newest pulsed field ablation technology.
HOMA-PULSE is a prospective observational study enrolling at least 120 non-diabetic patients undergoing their first AF ablation using pulsed field ablation at the Cardiocentrum, AGEL Hospital Trinec-Podlesi, Czech Republic.
On the day of ablation, fasting blood samples are collected as part of routine preoperative care. A portion of these samples is used to measure insulin resistance (HOMA-IR index, calculated from fasting glucose and insulin levels) along with additional biomarkers including GDF-15, hs-CRP, NT-proBNP, IL-6, and IL-1beta. Detailed procedural and clinical d...
Conditions: Atrial Fibrillation, Insulin Resistance, Catheter Ablation, Artificial Intelligence
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.